{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:17:02Z","timestamp":1790180222844,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T00:00:00Z","timestamp":1529884800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00330-018-5584-y","type":"journal-article","created":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T09:55:44Z","timestamp":1529920544000},"page":"299-308","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Twelve-month prostate volume reduction after MRI-guided transurethral ultrasound ablation of the prostate"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4811-0087","authenticated-orcid":false,"given":"David","family":"Bonekamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. B.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C.","family":"Roethke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pahernik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. A.","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Hatiboglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. H.","family":"Kuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. V.","family":"Popeneciu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L.","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Billia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Relle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hafron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. R.","family":"Nandalur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. M.","family":"Staruch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Burtnyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hohenfellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-P.","family":"Schlemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,25]]},"reference":[{"issue":"1","key":"5584_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7\u201330","journal-title":"CA Cancer J Clin"},{"issue":"17","key":"5584_CR2","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1001\/jama.293.17.2095","volume":"293","author":"PC Albertsen","year":"2005","unstructured":"Albertsen PC (2005) 20-Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer. JAMA 293(17):2095","journal-title":"JAMA"},{"issue":"5","key":"5584_CR3","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1056\/NEJMoa1209978","volume":"368","author":"MJ Resnick","year":"2013","unstructured":"Resnick MJ, Koyama T, Fan K-H et al (2013) Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer. N Engl J Med 368(5):436\u2013445","journal-title":"N Engl J Med"},{"issue":"30","key":"5584_CR4","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1200\/JCO.2015.62.5764","volume":"33","author":"JJ Tosoian","year":"2015","unstructured":"Tosoian JJ, Mamawala M, Epstein JI et al (2015) Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. J Clin Oncol 33(30):3379\u20133385","journal-title":"J Clin Oncol"},{"issue":"3","key":"5584_CR5","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","volume":"33","author":"L Klotz","year":"2015","unstructured":"Klotz L, Vesprini D, Sethukavalan P et al (2015) Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33(3):272\u2013277","journal-title":"J Clin Oncol"},{"issue":"2","key":"5584_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.eururo.2012.11.002","volume":"63","author":"A Napoli","year":"2013","unstructured":"Napoli A, Anzidei M, De Nunzio C et al (2013) Real-time magnetic resonance-guided high-intensity focused ultrasound focal therapy for localised prostate cancer: Preliminary experience. Eur Urol 63(2):395\u2013398","journal-title":"Eur Urol"},{"issue":"10","key":"5584_CR7","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1089\/end.2014.0881","volume":"29","author":"H Mendez","year":"2015","unstructured":"Mendez H, Passoni Maria N, Pow-Sang J, Jones Stephen J, Polascik J (2015) Comparison of Outcomes Between Preoperatively Potent Men Treated with Focal Versus Whole Gland Cryotherapy in a Matched Population. J Endourol 29(10):1193","journal-title":"J Endourol"},{"issue":"6","key":"5584_CR8","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/bju.12265","volume":"112","author":"AR Azzouzi","year":"2013","unstructured":"Azzouzi AR, Barret E, Moore CM et al (2013) TOOKAD\u00ae Soluble vascular-targeted photodynamic (VTP) therapy: Determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer. BJU Int 112(6):766\u2013774","journal-title":"BJU Int"},{"issue":"6","key":"5584_CR9","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.eururo.2015.04.029","volume":"68","author":"H Lepor","year":"2015","unstructured":"Lepor H, Llukani E, Sperling D, F\u00fctterer JJ (2015) Complications, Recovery, and Early Functional Outcomes and Oncologic Control Following In-bore Focal Laser Ablation of Prostate Cancer. Eur Urol 68(6):924\u2013926","journal-title":"Eur Urol"},{"issue":"3","key":"5584_CR10","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.juro.2016.02.2986","volume":"196","author":"KS Murray","year":"2016","unstructured":"Murray KS, Ehdaie B, Musser J et al (2016) Pilot Study to Assess Safety and Clinical Outcomes of Irreversible Electroporation for Partial Gland Ablation in Men with Prostate Cancer. J Urol. United States 196(3):883\u2013890","journal-title":"J Urol. United States"},{"issue":"4","key":"5584_CR11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.brachy.2013.02.002","volume":"12","author":"JM Cosset","year":"2013","unstructured":"Cosset JM, Cathelineau X, Wakil G et al (2013) Focal brachytherapy for selected low-risk prostate cancers: A pilot study. Brachytherapy 12(4):331\u2013337","journal-title":"Brachytherapy"},{"key":"5584_CR12","doi-asserted-by":"crossref","unstructured":"Zlotta AR, Djavan B, Matos C et al (1998) Percutaneous transperineal radiofrequency ablation of prostate tumour: safety, feasibility and pathological effects on human prostate cancer. Br J Urol 81(2):265\u2013275","DOI":"10.1046\/j.1464-410X.1998.00504.x"},{"issue":"1","key":"5584_CR13","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1148\/radiology.214.1.r00ja06290","volume":"214","author":"JC Chen","year":"2000","unstructured":"Chen JC, Moriarty JA, Derbyshire JA et al (2000) Prostate Cancer: MR Imaging and Thermometry during Microwave Thermal Ablation-Initial Experience. Radiology 214(1):290\u2013297","journal-title":"Radiology"},{"key":"5584_CR14","doi-asserted-by":"publisher","unstructured":"Valerio M, Cerantola Y, Eggener SE et al (2016) New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. Eur Urol 71(1):17\u201334. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2016.08.044","DOI":"10.1016\/j.eururo.2016.08.044"},{"key":"5584_CR15","doi-asserted-by":"publisher","unstructured":"Feijoo ERC, Sivaraman A, Barret E et al (2016) Focal High-intensity Focused Ultrasound Targeted Hemiablation for Unilateral Prostate Cancer: A Prospective Evaluation of Oncologic and Functional Outcomes. Eur Urol 69(2):214\u2013220. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2015.06.018","DOI":"10.1016\/j.eururo.2015.06.018"},{"key":"5584_CR16","doi-asserted-by":"publisher","unstructured":"Radtke JP, Wiesenfarth M, Kesch C et al (2017) Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies. Eur Urol. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2017.03.039","DOI":"10.1016\/j.eururo.2017.03.039"},{"issue":"3","key":"5584_CR17","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/pcan.2016.16","volume":"19","author":"JP Radtke","year":"2016","unstructured":"Radtke JP, Kuru TH, Bonekamp D et al (2016) Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance. Prostate Cancer Prostatic Dis 19(3):283\u2013291","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"5584_CR18","doi-asserted-by":"crossref","unstructured":"Valerio M, Donaldson I, Emberton M et al (2015) Detection of clinically significant prostate cancer using magnetic resonance imaging-ultrasound fusion targeted biopsy: A systematic review. Eur Urol 68(1):8\u201319","DOI":"10.1016\/j.eururo.2014.10.026"},{"issue":"10071","key":"5584_CR19","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"389","author":"HU Ahmed","year":"2017","unstructured":"Ahmed HU, El-Shater Bosaily A, Brown LC et al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389(10071):815\u2013822","journal-title":"Lancet"},{"issue":"4","key":"5584_CR20","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1001\/jama.2014.17942","volume":"1210","author":"MM Siddiqui","year":"2016","unstructured":"Siddiqui MM, Rais-Bahrami S, Turkbey B et al (2016) Comparison of MR\/Ultrasound Fusion\u2013Guided Biopsy With Ultrasound-Guided Biopsy for the Diagnosis of Prostate Cancer. JAMA 1210(4):390\u2013397","journal-title":"JAMA"},{"issue":"6","key":"5584_CR21","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/mrm.1910340606","volume":"34","author":"Y Ishihara","year":"1995","unstructured":"Ishihara Y, Calderon A, Watanabe H et al (1995) A precise and fast temperature mapping using water proton chemical shift. Magn Reson Med 34(6):814\u2013823","journal-title":"Magn Reson Med"},{"issue":"2","key":"5584_CR22","doi-asserted-by":"publisher","first-page":"W177","DOI":"10.2214\/AJR.14.13098","volume":"205","author":"S Ghai","year":"2015","unstructured":"Ghai S, Louis AS, Van Vliet M et al (2015) Real-time MRI-guided focused ultrasound for focal therapy of locally confined low-risk prostate cancer: Feasibility and preliminary outcomes. Am J Roentgenol 205(2):W177\u2013W184","journal-title":"Am J Roentgenol"},{"issue":"6","key":"5584_CR23","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.juro.2016.07.074","volume":"196","author":"SE Eggener","year":"2016","unstructured":"Eggener SE, Yousuf A, Watson S, Wang S, Oto A (2016) Phase II Evaluation of Magnetic Resonance Imaging Guided Focal Laser Ablation of Prostate Cancer. J Urol. United States 196(6):1670\u20131675","journal-title":"J Urol. United States"},{"key":"5584_CR24","doi-asserted-by":"crossref","unstructured":"Chopra R, Tang K, Burtnyk M et al (2009) Analysis of the spatial and temporal accuracy of heating in the prostate gland using transurethral ultrasound therapy and active MR temperature feedback. Phys Med Biol 54(9):2615\u20132633","DOI":"10.1088\/0031-9155\/54\/9\/002"},{"key":"5584_CR25","doi-asserted-by":"crossref","unstructured":"Ramsay E, Mougenot C, Staruch R et al (2017) Evaluation of Focal Ablation of Magnetic Resonance Imaging Defined Prostate Cancer Using Magnetic Resonance Imaging Controlled Transurethral Ultrasound Therapy with Prostatectomy as the Reference Standard. J Urol 197(1):255\u2013261","DOI":"10.1016\/j.juro.2016.06.100"},{"issue":"3","key":"5584_CR26","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2015.12.029","volume":"70","author":"JL Chin","year":"2016","unstructured":"Chin JL, Billia M, Relle J et al (2016) Magnetic Resonance Imaging\u2013Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial. Eur Urol 70(3):447\u2013455","journal-title":"Eur Urol"},{"key":"5584_CR27","doi-asserted-by":"crossref","unstructured":"Chopra R, Colquhoun A, Burtnyk M et al (2012) MR imaging-controlled transurethral ultrasound therapy for conformal treatment of prostate tissue: initial feasibility in humans. Radiology 265(1):303\u2013313","DOI":"10.1148\/radiol.12112263"},{"issue":"6","key":"5584_CR28","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/0360-3016(84)90379-1","volume":"10","author":"SA Sapareto","year":"1984","unstructured":"Sapareto SA, Dewey WC (1984) Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys 10(6):787\u2013800","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"5584_CR29","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1148\/radiology.216.2.r00au42517","volume":"216","author":"NJ McDannold","year":"2000","unstructured":"McDannold NJ, King RL, Jolesz FA, Hynynen KH (2000) Usefulness of MR imaging-derived thermometry and dosimetry in determining the threshold for tissue damage induced by thermal surgery in rabbits. Radiology 216(11):517\u2013523","journal-title":"Radiology"},{"key":"5584_CR30","doi-asserted-by":"crossref","unstructured":"Burtnyk M, Hill T, Cadieux-Pitre H, Welch I (2015) Magnetic resonance image guided transurethral ultrasound prostate ablation: a preclinical safety and feasibility study with 28-day followup. J Urol 193(5):1669\u20131675","DOI":"10.1016\/j.juro.2014.11.089"},{"issue":"22","key":"5584_CR31","doi-asserted-by":"publisher","first-page":"6817","DOI":"10.1088\/0031-9155\/55\/22\/014","volume":"55","author":"M Burtnyk","year":"2010","unstructured":"Burtnyk M, N\u2019Djin WA, Kobelevskiy I, Bronskill M, Chopra R (2010) 3D conformal MRI-controlled transurethral ultrasound prostate therapy: validation of numerical simulations and demonstration in tissue-mimicking gel phantoms. Phys Med Biol. England 55(22):6817\u20136839","journal-title":"Phys Med Biol. England"},{"key":"5584_CR32","doi-asserted-by":"crossref","unstructured":"Burtnyk M, Chopra R, Bronskill M (2010) Simulation study on the heating of the surrounding anatomy during transurethral ultrasound prostate therapy: a 3D theoretical analysis of patient safety. Med Phys 37(6):2862\u20132875","DOI":"10.1118\/1.3426313"},{"issue":"3","key":"5584_CR33","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.juro.2007.05.011","volume":"178","author":"A Boyes","year":"2007","unstructured":"Boyes A, Tang K, Yaffe M, Sugar L, Chopra R, Bronskill M (2007) Prostate Tissue Analysis Immediately Following Magnetic Resonance Imaging Guided Transurethral Ultrasound Thermal Therapy. J Urol 178(3):1080\u20131085","journal-title":"J Urol"},{"key":"5584_CR34","doi-asserted-by":"crossref","unstructured":"Ritter BF, Boskamp T, Homeyer A et al (2011) Medical Image Analysis: A Visual Approach. IEEE Pulse 2(6):60\u201370","DOI":"10.1109\/MPUL.2011.942929"},{"issue":"4","key":"5584_CR35","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s11548-013-0840-8","volume":"8","author":"M Nolden","year":"2013","unstructured":"Nolden M, Zelzer S, Seitel A et al (2013) The medical imaging interaction toolkit: Challenges and advances: 10 years of open-source development. Int J Comput Assist Radiol Surg 8(4):607\u2013620","journal-title":"Int J Comput Assist Radiol Surg"},{"issue":"11","key":"5584_CR36","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1002\/pros.21154","volume":"70","author":"K Biermann","year":"2010","unstructured":"Biermann K, Montironi R, Lopez-Beltran A, Zhang S, Cheng L (2010) Histopathological findings after treatment of prostate cancer using high-intensity focused ultrasound (HIFU). Prostate 70(11):1196\u20131200","journal-title":"Prostate"},{"issue":"8","key":"5584_CR37","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1136\/jclinpath-2011-200460","volume":"65","author":"P Ryan","year":"2012","unstructured":"Ryan P, Finelli A, Lawrentschuk N et al (2012) Prostatic needle biopsies following primary high intensity focused ultrasound (HIFU) therapy for prostatic adenocarcinoma: histopathological features in tumour and non-tumour tissue. J Clin Pathol 65(8):729\u2013734","journal-title":"J Clin Pathol"},{"issue":"3","key":"5584_CR38","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2307\/1932409","volume":"26","author":"LR Dice","year":"1945","unstructured":"Dice LR (1945) Measures of the Amount of Ecologic Association Between Species. Ecology 26(3):297\u2013302","journal-title":"Ecology"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00330-018-5584-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-018-5584-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-018-5584-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T08:43:06Z","timestamp":1561452186000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00330-018-5584-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,25]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["5584"],"URL":"https:\/\/doi.org\/10.1007\/s00330-018-5584-y","relation":{},"ISSN":["0938-7994","1432-1084"],"issn-type":[{"value":"0938-7994","type":"print"},{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,25]]},"assertion":[{"value":"8 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Heinz-Peter Schlemmer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"David Bonekamp is speaker for Profound Medical Inc.Mathieu Burtnyk is director of clinical affairs of Profound Medical Inc. with a salary and stock options.Robert Staruch is senior clinical scientist at Profound Medical Inc., with a salary and stock options.Jason M. Hafron declares: Amgen-paid speaker, Armune Biosciences Inc, advisory board\/paid speaker, Dendreon-Advisory Board, paid speaker, Myriad, and paid speaker, United Physicians- Board of directorsHeinz-Peter Schlemmer declares: Consulting fee or honorarium: Siemens, Curagita, Profound, Bayer. Travel support: Siemens, Curagita, Profound, Bayer. Board Member: Curagita. Consultancy: Curagita, Bayer. Grants\/Grants pending: BMBF, Deutsche Krebshilfe, Dietmar-Hopp-Stiftung, Roland-Ernst-Stiftung. Payment for lectures: Siemens, Curagita, Profound, Bayer.Boris Hadaschik declares: Personal fees: Janssen, BMS, Astrellas, Bayer. Grants: Janssen, Astrellas, BMS, German Cancer Aid, German Research Foundation.Grant: Profound Medical.Gencay Hatiboglu declares: Consultancy for BMS.Timur Kuru has nothing to declare.James Relle has nothing to declare.Maya Mueller-Wolf has nothing to declare.Matthias R\u00f6thke declares consulting fee and payment for lectures: Siemens Healthineers, Curagita AG.Sascha Pahernik reports personal fees from Bayer, personal fees from Astellas, personal fees from Janssen, outside the submitted work.Valentin Popeneciu has nothing to declare.Joseph Chin declares: Investigator and consultant for Profound Medical Inc., US HIFU, Endocare; Paid Advisory Board\/Consultancy for Abbvie, Johnson & Johnson\/Janssen, Amgen, Tersera, Novartis, Astellas, Bayer, Sanofi-Aventis.Michele Billia has nothing to declare.Kiran Nandalur has nothing to declare.Markus Hohenfellner has nothing to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was obtained from all subjects (patients) in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Some study subjects or cohorts have been previously reported in Chin JL, Billia M, Relle J, et al. Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer: a prospective Phase 1 clinical trial. Eur Urol. 2016;70(3):447\u2013455.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"value":"\u2022 prospective\u2022 experimental\u2022 multicentre study","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}